Alpback Workshop

MENU menu

9th Alpbach Workshop on
Affinity Proteomics
March 11-13 2019



Cambridge Protein Arrays Ltd are the European distributors and service providers for HuProt™ arrays, the largest human protein arrays available, with more than 19,000 human proteins, representing more than 15,000 human genes on a single slide. HuProt™ arrays are designed for screening of antibody specificity, autoimmune profiling, and protein interactions. Cambridge Protein Arrays Ltd. is a biotech SME founded in 2010 by Mike Taussig, located in Cambridge, UK. With strong roots in the European Affinity Proteomics community, we are also the organisers of the 9th Alpbach Workshop in Affinity Proteomics.

Cambridge Protein Arrays


Explore our extensive portfolio of more than 74,000 high-quality primary and secondary antibodies ( covering over 85% of the proteome, supported by an extensive range of antibody-related products and custom services. Our antibody assays are validated by thousands of citations worldwide, helping you achieve superior results in a wide range of detection and purification applications.



Qlucore  provides next-generation bioinformatic software for researchers in life science, plant and biotech industries, as well as academia, worldwide. Qlucore Omics Explorer is so easy to use that a user no longer has to depend on a bioinformatics expertise to undertake initial exploration and data analysis. The Qlucore software works with broad ranges of Omics data – Proteomics, RNA-seq, gene expression, miRNA, DNA-methylation, metabolomics, flow cytometry, clinical data etc. and differs from traditional software by giving highly interactive visualizations in both 2D and 3D. The program is lightning fast with plots and updates being presented instantaneously e.g. PCA plots, heatmaps, t-SNE and Volcano plots etc.


As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways. Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.


The Antibody Society is a non-profit association representing individuals and organizations involved in antibody research and development. We engage in activities that broadly benefit our members, such as education and publishing, encourage collaboration between companies, academia and government organizations, and help to organize conferences. As a global association, the Society engages with government and international agencies to discuss issues of importance to the antibody community. 


Atlas Antibodies develop, produce and market reagents for proteomic research. The products include thoroughly validated antibodies and labelled and unlabeled protein fragments for both qualitative and quantitative analysis of human proteins. The goal is to offer reagents targeting all human proteins and with more than 55,000 products, over 80% of all human proteins are currently covered. The products are marketed and sold both directly to end users worldwide and through several global and local distributors. Atlas Antibodies is a spin-out from the Swedish Human Protein Atlas (HPA) project and the majority of the research products have been developed by the HPA project for the purpose of creating a map of human protein expression and localization in normal tissues, cancers and cell lines.

Atlas Antibodies


IONTAS offers services for the discovery of antibodies using proprietary Phage Display Technology. Our services draw upon extensive experience in antibody engineering and assay development covering a wide range of targets. Each project is tailored to the specific requirements of each Partner, which facilitates delivery of project objectives in a timely manner. In addition to services, IONTAS develops phage libraries for out-licencing; and is developing other proprietary antibody discovery platforms to generate antibodies against difficult targets.



YUMAB’s antibody discovery technology platform provides access to human, natural, close to germline antibody candidates, with low immunogenicity, large epitope diversity, high success rates even for difficult targets like GPCRs, and pre-designed properties like interspecies cross-reactivity or specific epitope targeting. YUMAB antibodies are highly developable for all clinical indications and antibody formats, including full-length IgG and Fab, scFv, bispecifics, chimeric antigen receptors (CARs), antibody fusion proteins and conjugates (ADCs). YUMAB's portfolio covers target discovery, validation and production, personalized patient libraries, optimized antibody discovery solutions and lead development, with flexible fee-for-service solutions and collaborative partnerships.




SomaLogic delivers meaningful and actionable health-management insights that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives. These essential insights, provided through a global network of partners and users, are derived from precise, proprietary, and personalized measurement of critical changes in an individual's proteins throughout life.



Swedish company Olink Proteomics provides innovative solutions for targeted human protein biomarker discovery. Proseek® Multiplex enables rapid, high-throughput analysis, exceptional data quality and minimal sample consumption. Using our Proximity Extension Assay (PEA) technology, 1µl samples are analysed for 92 biomarkers simultaneously, with exceptional readout specificity. Disease-focused panels are designed together with leading experts, with full transparency on our rigorous validation data. Proseek Multiplex is available as ready-to-use kits or via our fee-for service offering.

Olink Proteomics


Absolute Antibody specialises in the sequencing, engineering, and recombinant production of antibodies. We can sequence from cell lines or from purified antibody protein. Our engineering services include species/isotype switching, full humanisation, generation of custom bispecifics, and more! Our expression platform caters for milligram to gram quantities with delivery in as little as 4 weeks. All services are royalty free. We also offer a reagents catalogue that includes antibodies against common immune checkpoints, and a range of research-grade biosimilars. We're always excited to hear about new ideas and potential collaborations - ask us how we could help you at Alpbach in 2019!

Absolute Antibody


CDI Laboratories produces the largest protein microarray available.  CDI’s HuProtTM array contains ~75% of the human proteome. CDI Laboratories sells the HuProtTM as a standalone product as well as used in the following services: biomarker discovery in oncology and autoimmune disease, predictive diagnostic assay development, autoimmune profiling, protein interactome assays. CDI participated in the NIH Protein Capture Reagents Program and has produced ~ 1500 monoclonal antibodies all tested for cross reactivity against HuProtTM. Journals and funding agencies are increasing their standards regarding the reagents used. CDI can produce truly monospecific antibodies to meet these new standards and concerns.

Nextgen Proteomics


Next generation tumour-directed immunotherapies.

Alligator develops antibody-based drugs for tumor-directed immunotherapy. The Company is primarily active in the early phases of drug development, from the idea stage until to clinical trials in phase IIa. Alligator’s first clinical asset, ADC-1013, is an agonistic antibody targeting the CD40 receptor. It is currently in clinical phase I in cancer patients and has been licensed to Janssen Biotech. The bispecific antibody Ator-1015 is a first in class immunotherapy targeting OX40 and CTLA-4. It is in preclinical development and will enter clinical phase in the first half of 2018.

Alligator Bioscience


Immunovia (Lund, Sweden) is a life science company focused on developing blood based tests for cancer and autoimmune diseases. Immunovia´s core technology, IMMray™, is based on antibody biomarker microarray analysis. IMMray™ PanCan-d, now undergoing clinical validation, could be the first blood based test for early diagnosis of pancreatic cancer. The IMMray technology is generally applicable to develop solutions to unmet needs within cancer and autoimmunity. The company has started a programme focused on autoimmune diseases diagnosis, prognosis and therapy monitoring based on studies with Rheumatoid Arthritis, SLE, Vasculaitis and Sjögrens Syndrome. Additionally Immunovia has recently announced promising results within lung cancer.



CiteAb is a leading life science data provider that helps researchers and their suppliers make more informed decisions. Our antibody search engine provides a simple way for researchers to find antibodies that work, while our high quality market data and citations are used commercially by many of the world’s leading reagent suppliers and investment companies.

Alligator Bioscience


PEPperPRINT offers high-density peptide microarrays as well as linear and conformational epitope mapping services for antibody validation. Moreover, PEPperPRINT provides the Human Epitome Microarray with more than 23,000 human database epitopes for antibody cross-reactivity profiling and numerous other peptide microarrays for cancer, infectious disease and autoimmune research. Based on its proprietary laser-printing technology, PEPperPRINT can synthesize tens of thousands of peptides directly on the chip. The peptide microarray content can be easily customized– project by project. Recently, PEPperPRINT has broadened its product portfolio in biomarker discovery by introducing its neoepitope discovery platform for the identification of cancer biomarkers and the SeroRA® library for the development of IVD and CDx in rheumatoid arthritis.



Sciomics offers high-content analysis services for >1,000 proteins in a single assay including changes of their phosphorylation and ubiquitination status. The service is used by our customers from pharmaceutical companies and biomedical research institutes for analysis of pathway activity, elucidation of disease mechanisms, drug mode-of-action analysis, comparing different drug compounds,discovery of novel drug targets and identification and verification of protein biomarkers. The target proteins are carefully selected keyplayers in the most important biomedical pathways. Our immuno-based antibody array platform guarantees robust and reproducible results which can easily be translated into clinical assays. In addition to these CRO activities, Sciomics is active in the early-phase development of novel diagnostic means for precision medicine with a focus on cancer as well as organ failure.



Specifica specializes in delivering precisely configured, unique libraries of developable antibodies under simple, exclusive and semi-exclusive business terms. Libraries are designed to client specifications: scFv or Fab; phage or yeast; natural, synthetic or hybrid; all V genes, or a selected subset. Genetic diversity is validated by next-generation sequencing using proprietary bioinformatics protocols. Specifica also provides antibody discovery services, combining phage display, yeast display and advanced next generation sequencing and bioinformatic analysis to identify panels of antibodies with broad binding specificities, as well as the maturation of selected or client antibodies for affinity, specificity or developability.



The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,200 scientists investigate how cancer develops, identify cancer risk factors and work at new strategies to prevent people from getting cancer. They develop novel approaches to make tumour diagnosis more precise and treatment of cancer patients more successful.




The Jackson Laboratory is a leading provider of a wide range of mouse models and services for immunology, immuno-oncology, autoimmunity, and inflammation research.   Drawing on decades of research experience, we provide capabilities around mouse model selection and husbandry to help clients and researchers evaluate novel therapies. Learn more at


VIB is a life sciences research institute in Flanders, Belgium. More than 1470 scientists from over 66 countries perform basic research into the molecular foundations of life. The institute offers a program of international VIB conferences in various VIB research fields. From day one VIB has supported and sponsored scientific conferences to help VIB scientists network with their colleagues. In 2014 the VIB Conference Series was launched to further expand these activities and support them with a dedicated professional team.